Business
BioAtla Announces Change in Executive Leadership
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of
About this update from Bioatla, Inc.
[{"type":"text","content":"SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that its President, Scott Smith, will be leaving the Company to pursue a new opportunity as Chief Executive Officer at Viatris (Nasdaq: VTRS), a large, global healthcare pharmaceutical company. Scott will continue his relationship with BioAtla by serving as a Board of Directors member for the Company. “We extend our sincere thanks to Scott for his important contributions since joining the Company in 2018 and wish him well in his new endeavor,” said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla. “Scott’s extensive experience in biotechnology and pharmaceutical executive leadership roles has helped the expansion of the Company’s operations and advancement of our pipeline and clinical programs. We are pleased Scott will continue as a Board member for BioAtla, as his expertise, knowledge, vision, energy, and passion will be invaluable to our Company.” “It has been a privilege working with the amazing group of colleagues at BioAtla. I am proud of all that BioAtla has accomplished and the impact the Company continues to make in its mission to improve patients’ lives. I am looking forward to continuing my relationship with BioAtla as a Board member and excited about the Company’s evolving CAB product portfolio,” said Scott Smith. About BioAtla®, Inc.BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with 704 patents (430 issued, 5 allowed, and 269 pending). Broad patent coverage in all major markets ...